RxDoctor Payments Data

Kristine Jakiemiec, PA

Physician Assistant · Palmer, AKNPI 1922158864

Payments from drug & device makers

$660in general payments, 2019–2025

Across 13 payments — averaging $50.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$160
  • Bayer$150
  • Novo Nordisk$127
  • AstraZeneca$110
  • Exact Sciences$30
  • Inspire Medical Systems, Inc.$24
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$62895%
  • Education$325%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660 in reported general payments places this provider in the 75th percentile of 365 physician assistant providers in Alaska.

See all physician assistant providers in Alaska

Medicare billing

Part B allowed, 2024
$76,879
Medicare patients
202
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$50,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$49,570
OzempicSemaglutide37$41,959
EliquisApixaban45$38,514
MyrbetriqMirabegron33$31,690
JanuviaSitagliptin Phosphate20$29,497
ProliaDenosumab11$18,651
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$16,859
Dexlansoprazole DrDexlansoprazole16$11,750
LinzessLinaclotide18$9,093
OxycontinOxycodone Hcl11$5,029
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$2,367
Albuterol Sulfate HfaAlbuterol Sulfate43$2,043
Estradiol30$2,037
Duloxetine Hcl44$1,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$127$41,95937 claims
PfizerEliquis$22$38,51445 claims
AmgenProlia$160$18,65111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 365 physician assistant providers in Alaska.

Other physician assistant in Palmer

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →